Skip Fleshman
Partner @ Asset Management Ventures (AMV)
Palo Alto, United States
Skip Fleshman is a Series A investor at Asset Management Ventures (AMV) in Palo Alto focused on Health Care and Software. Skip Fleshman is based out of San Francisco, California and is the Partner of Aulis Capital and Managing Partner of Asset Management Ventures. Skip previously worked at United States Air Force as a Officer. Skip Fleshman attended the Stanford Graduate School of Business.
- Total investments:
- 55
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries Skip Fleshman invests in
Stages Skip Fleshman invests in
Countries Skip Fleshman invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 15 (27%)
- Software 12 (22%)
- Medical 7 (13%)
- Internet 4 (7%)
- SaaS 3 (5%)
Stage
- Series A 13 (24%)
- Seed 10 (18%)
- Series B 10 (18%)
- Debt Financing 4 (7%)
- Series C 3 (5%)
Country
- United States 26 (47%)
- South Korea 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Autonomize AI is a human-centric AI platform that learns from multi-structured clinical and biomedical data and pairs it with human context to aid decision-making and data discovery. They extract contextual information from multi-structured healthcare data, enrich with human know-how, and aid decision-making and data discovery. | $28M / Series A / Jun 12, 2025 | ||
| Outcomes4Me provides an AI-powered digital platform designed to assist cancer patients in managing their care. The platform integrates clinical guidelines, genomic data, and clinical trial information to offer personalized treatment options. Patients can access features such as symptom tracking, medication management, and tailored clinical trialmatching. Outcomes4Me also facilitates the organization and understanding of medical records, enabling users to make informed decisions in collaboration with their healthcare providers. The platform is developed in collaboration with experts in oncology and aims to support patients throughout their treatment journey. | $21M / Series A / May 29, 2025 | ||
| Autonomize AI is a human-centric AI platform that learns from multi-structured clinical and biomedical data and pairs it with human context to aid decision-making and data discovery. They extract contextual information from multi-structured healthcare data, enrich with human know-how, and aid decision-making and data discovery. | $4M / Seed / Apr 10, 2023 | ||
| SubjectWell is the risk-free clinical trials marketplace for patient recruitment | $35M / Series B / Oct 18, 2022 | ||
| Marley Medical is a virtual primary care clinic, focused on people with common chronic diseases. | $9M / Seed / Oct 14, 2021 | ||
| Outcomes4Me provides an AI-powered digital platform designed to assist cancer patients in managing their care. The platform integrates clinical guidelines, genomic data, and clinical trial information to offer personalized treatment options. Patients can access features such as symptom tracking, medication management, and tailored clinical trialmatching. Outcomes4Me also facilitates the organization and understanding of medical records, enabling users to make informed decisions in collaboration with their healthcare providers. The platform is developed in collaboration with experts in oncology and aims to support patients throughout their treatment journey. | $12M / Series A / Apr 28, 2021 | ||
| Carta empowers hospitals to personalize the delivery of care to the individual needs of each patient. The approach Carta Healthcare is advocating and enabling is to: find past patients similar to the current one being treated; quantify what exactly happened to them during their journey through the hospital (this is where our model comes in) and;use machine learning to project what the particular patient in question will need, and what the patient can expect their experience to be in the hospital. Carta was founded in 2017 and is based in Palo Alto, California, United States. | $17.3M / Series A / Apr 07, 2021 | ||
| Outcomes4Me provides an AI-powered digital platform designed to assist cancer patients in managing their care. The platform integrates clinical guidelines, genomic data, and clinical trial information to offer personalized treatment options. Patients can access features such as symptom tracking, medication management, and tailored clinical trialmatching. Outcomes4Me also facilitates the organization and understanding of medical records, enabling users to make informed decisions in collaboration with their healthcare providers. The platform is developed in collaboration with experts in oncology and aims to support patients throughout their treatment journey. | $4.7M / Seed / Nov 18, 2020 | ||
| Lark is a developer of chronic disease prevention and management platform used to prevent chronic conditions. The company uses cutting-edge AI combined with human coaches and connected devices to provide real-time, personalized, 24/7 support, and counseling to help users make healthier choices and manage their conditions. Its CDC-recognizedDiabetes Prevention Program, Wellness Program, Diabetes Care Program, and Hypertension Program have 1.5 million users and have demonstrated clinically validated improved health outcomes published in 11 peer-reviewed journals and analyst reports.Lark was founded by Julia Hu and Jeff Zira in 2011 and is headquartered in Mountain View, California. | $55M / Series C / Oct 08, 2020 | ||
| Reify Health provides cloud-based software that helps accelerate the development of new, life-saving therapies. The company's system accelerates enrollment timelines and the overall pace of research, enabling research sponsors and coordinators to focus on the actions that impact clinical research success. Reify Health product StudyTeam is acloud-based software that helps clinical trial teams achieve faster, more predictable enrollment while eliminating the tedious work that saps productivity and study budget. It gives sponsors, CROs, and clinical research sites earlier visibility to the full enrollment picture, and the insight they need to focus on people and capital on work that yields the greatest return. | $30M / Series B / Aug 12, 2020 | ||
| See all 55 investments → | |||
Co-Investors
AMV is a venture capital firm investing in early-stage digital health, tech, and life sciences companies. The firm has provided early-stage financing for ground-breaking companies such as Amgen, Tandem Computer, and Applied BioSystems. Asset Management was founded in 1965 by venture capitalist Franklin "Pitch" Johnson in Palo Alto, California.
Asset Management Ventures (AMV) Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Rich Simoni
Managing Partner
|
|||
|
Skip Fleshman
Partner
|
|||
Louis Lange
Partner
|
|||
|
Pitch Johnson
Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Skip Fleshman invest in?
Skip Fleshman invests primarily in Health Care, Software and Medical startups, most often at Series A and Seed stage. Most of the 55 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Skip Fleshman?
Public channels for Skip Fleshman include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Skip Fleshman last invest?
The most recent investment recorded for Skip Fleshman closed in Jun 2025. Shizune tracks 55 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
